NASDAQ:RNLX
Renalytix AI plc Stock News
$0.352
-0.105 (-22.91%)
At Close: Jun 25, 2024
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
07:00am, Friday, 14'th Jun 2024
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequ
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
06:15pm, Wednesday, 15'th May 2024
Renalytix Plc (NASDAQ:RNLX ) Q3 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - C
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
07:00am, Wednesday, 15'th May 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical manageme
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
07:00am, Thursday, 09'th May 2024
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, Ma
Renalytix Announces Financing with Expected Size of up to $4 Million
07:00am, Monday, 08'th Apr 2024
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75
3 Ridiculously Enticing Stocks to Buy for Under a Buck
03:58pm, Monday, 25'th Mar 2024
Let's keep it real in this joint – you should generally avoid stocks under $1. Yes, they're “cheap” but that's not necessarily a good thing.
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
07:00am, Thursday, 14'th Mar 2024
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
07:00am, Thursday, 15'th Feb 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on o
Renalytix slides by a third as funding moves front and centre
06:38am, Thursday, 15'th Feb 2024
Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is develo
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09:00am, Friday, 09'th Feb 2024
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG Me
Renalytix rises on draft Medicare determination
05:44am, Friday, 09'th Feb 2024
Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid S
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
07:00am, Wednesday, 10'th Jan 2024
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
Renalytix Plc (RNLX) Q1 2024 Earnings Call Transcript
11:18am, Tuesday, 14'th Nov 2023
Renalytix Plc (NASDAQ:RNLX ) Q1 2024 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Howard Doran
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
07:00am, Tuesday, 14'th Nov 2023
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
07:00am, Tuesday, 07'th Nov 2023
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, Nov